| 1. Executive Summary |
| 2. Global Lung Cancer Treatment Market Introduction |
| 2.1. Global Lung Cancer Treatment Market – Taxonomy |
| 2.2. Global Lung Cancer Treatment Market –Definitions |
| 2.2.1. By Surgery |
| 2.2.2. By Chemotherapy |
| 2.2.3. By Radiotherapy |
| 2.2.4. By Targeted therapy |
| 2.2.5. By Immunotherapy |
| 2.2.6. By Region |
| 3. Global Lung Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Lung Cancer Treatment Market Dynamic Factors - Impact Analysis |
| 3.6. Global Lung Cancer Treatment Market – Competition Landscape |
| 4. Global Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 |
| 4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Lung Cancer Treatment Market, By Surgery, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1. Lobectomy |
| 5.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. A Wedge Resection |
| 5.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Segmentectomy |
| 5.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Pneumonectomy |
| 5.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Lung Cancer Treatment Market, By Chemotherapy, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.1. Carboplatin or Cisplatin |
| 6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Docetaxel (Taxotere) |
| 6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Gemcitabine (Gemzar) |
| 6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Nab-Paclitaxel (Abraxane) |
| 6.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Paclitaxel (Taxol) |
| 6.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Premetxed (Alimta) |
| 6.6.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Vinorelbine (Navelbine) |
| 6.7.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7. Global Lung Cancer Treatment Market, By Radiotherapy, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1. External Beam |
| 7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Internal Beam |
| 7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Lung Cancer Treatment Market, By Targeted therapy, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1. Epidermal Growth Factor Receptor (EGFR) Inhibitors |
| 8.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Anaplastic Lymphoma Kinase (ALK) Inhibitors |
| 8.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Drugs Targeting ROS1 Genetic Changes |
| 8.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Drugs Targeting RET Fusion |
| 8.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Anti-angiogenesis Therapy |
| 8.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. Global Lung Cancer Treatment Market, By Immunotherapy, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.1. Atezolizuamb (Tecentriq) |
| 9.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Cemiplimab (Libtayo) |
| 9.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Darvalumab (lmfinzi) |
| 9.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Nivolumab (Opdivo) |
| 9.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Pembrolizumab (Keytruda) |
| 9.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. Global Lung Cancer Treatment Market Forecast, By Region, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.1. North America |
| 10.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.1.3. Market Opportunity Analysis |
| 10.2. Europe |
| 10.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.2.3. Market Opportunity Analysis |
| 10.3. Asia-Pacific |
| 10.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.3.3. Market Opportunity Analysis |
| 10.4. Latin America |
| 10.4.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.4.3. Market Opportunity Analysis |
| 10.5. Middle East and Africa |
| 10.5.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 10.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 10.5.3. Market Opportunity Analysis |
| 10.6. Global Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Region, 2022-2028 |
| 11. North America Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 11.1. Surgery Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Lobectomy |
| 11.1.2. A wedge resection |
| 11.1.3. Segmentectomy |
| 11.1.4. Pneumonectomy |
| 11.2. Chemotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Carboplatin or cisplatin |
| 11.2.2. Docetaxel (Taxotere) |
| 11.2.3. Gemcitabine (Gemzar) |
| 11.2.4. Nab-paclitaxel (Abraxane) |
| 11.2.5. Paclitaxel (Taxol) |
| 11.2.6. Pemetrexed (Alimta) |
| 11.2.7. Vinorelbine (Navelbine) |
| 11.3. Radiotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. External Beam |
| 11.3.2. Internal Beam |
| 11.4. Targeted therapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. Epidermal growth factor receptor (EGFR) inhibitors |
| 11.4.2. Anaplastic lymphoma kinase (ALK) inhibitors |
| 11.4.3. Drugs targeting ROS1 genetic changes |
| 11.4.4. Drugs targeting RET fusion |
| 11.4.5. Anti-angiogenesis therapy |
| 11.5. Immunotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.5.2. Cemiplimab (Libtayo) |
| 11.5.3. Durvalumab (Imfinzi) |
| 11.5.4. Nivolumab (Opdivo) |
| 11.5.5. Pembrolizumab (Keytruda) |
| 11.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.6.1. USA |
| 11.6.2. Canada |
| 11.7. North America Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Country, 2022-2028 |
| 11.8. North America Lung Cancer Treatment Market Dynamics – Trends |
| 12. Europe Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 12.1. Surgery Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Lobectomy |
| 12.1.2. A wedge resection |
| 12.1.3. Segmentectomy |
| 12.1.4. Pneumonectomy |
| 12.2. Chemotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Carboplatin or cisplatin |
| 12.2.2. Docetaxel (Taxotere) |
| 12.2.3. Gemcitabine (Gemzar) |
| 12.2.4. Nab-paclitaxel (Abraxane) |
| 12.2.5. Paclitaxel (Taxol) |
| 12.2.6. Pemetrexed (Alimta) |
| 12.2.7. Vinorelbine (Navelbine) |
| 12.3. Radiotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. External Beam |
| 12.3.2. Internal Beam |
| 12.4. Targeted therapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Epidermal growth factor receptor (EGFR) inhibitors |
| 12.4.2. Anaplastic lymphoma kinase (ALK) inhibitors |
| 12.4.3. Drugs targeting ROS1 genetic changes |
| 12.4.4. Drugs targeting RET fusion |
| 12.4.5. Anti-angiogenesis therapy |
| 12.5. Immunotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Atezolizumab (Tecentriq) |
| 12.5.2. Cemiplimab (Libtayo) |
| 12.5.3. Durvalumab (Imfinzi) |
| 12.5.4. Nivolumab (Opdivo) |
| 12.5.5. Pembrolizumab (Keytruda) |
| 12.5.6. Heavy Commercial Vehicle |
| 12.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.6.1. Germany |
| 12.6.2. UK |
| 12.6.3. France |
| 12.6.4. Spain |
| 12.6.5. Italy |
| 12.6.6. Russia |
| 12.6.7. Rest of Europe |
| 12.7. Europe Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Country, 2022-2028 |
| 12.8. Europe Lung Cancer Treatment Market Dynamics – Trends |
| 13. Asia-Pacific Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 13.1. Surgery Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Lobectomy |
| 13.1.2. A wedge resection |
| 13.1.3. Segmentectomy |
| 13.1.4. Pneumonectomy |
| 13.2. Chemotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Carboplatin or cisplatin |
| 13.2.2. Docetaxel (Taxotere) |
| 13.2.3. Gemcitabine (Gemzar) |
| 13.2.4. Nab-paclitaxel (Abraxane) |
| 13.2.5. Paclitaxel (Taxol) |
| 13.2.6. Pemetrexed (Alimta) |
| 13.2.7. Vinorelbine (Navelbine) |
| 13.3. Radiotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. External Beam |
| 13.3.2. Internal Beam |
| 13.4. Targeted therapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Epidermal growth factor receptor (EGFR) inhibitors |
| 13.4.2. Anaplastic lymphoma kinase (ALK) inhibitors |
| 13.4.3. Drugs targeting ROS1 genetic changes |
| 13.4.4. Drugs targeting RET fusion |
| 13.4.5. Anti-angiogenesis therapy |
| 13.5. Immunotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Atezolizumab (Tecentriq) |
| 13.5.2. Cemiplimab (Libtayo) |
| 13.5.3. Durvalumab (Imfinzi) |
| 13.5.4. Nivolumab (Opdivo) |
| 13.5.5. Pembrolizumab (Keytruda) |
| 13.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.6.1. China |
| 13.6.2. India |
| 13.6.3. Japan |
| 13.6.4. ASEAN |
| 13.6.5. Australia & New Zealand |
| 13.6.6. Rest of Asia-Pacific |
| 13.7. Asia-Pacific Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Country, 2022-2028 |
| 13.8. Asia-Pacific Lung Cancer Treatment Market Dynamics – Trends |
| 14. Latin America Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 14.1. Surgery Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Lobectomy |
| 14.1.2. A wedge resection |
| 14.1.3. Segmentectomy |
| 14.1.4. Pneumonectomy |
| 14.2. Chemotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1. Carboplatin or cisplatin |
| 14.2.2. Docetaxel (Taxotere) |
| 14.2.3. Gemcitabine (Gemzar) |
| 14.2.4. Nab-paclitaxel (Abraxane) |
| 14.2.5. Paclitaxel (Taxol) |
| 14.2.6. Pemetrexed (Alimta) |
| 14.2.7. Vinorelbine (Navelbine) |
| 14.3. Radiotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1. External Beam |
| 14.3.2. Internal Beam |
| 14.4. Targeted therapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. Epidermal growth factor receptor (EGFR) inhibitors |
| 14.4.2. Anaplastic lymphoma kinase (ALK) inhibitors |
| 14.4.3. Drugs targeting ROS1 genetic changes |
| 14.4.4. Drugs targeting RET fusion |
| 14.4.5. Anti-angiogenesis therapy |
| 14.5. Immunotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Atezolizumab (Tecentriq) |
| 14.5.2. Cemiplimab (Libtayo) |
| 14.5.3. Durvalumab (Imfinzi) |
| 14.5.4. Nivolumab (Opdivo) |
| 14.5.5. Pembrolizumab (Keytruda) |
| 14.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.6.1. Brazil |
| 14.6.2. Mexico |
| 14.6.3. Rest of Latin America |
| 14.7. Latin America Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Country, 2022-2028 |
| 14.8. Latin America Lung Cancer Treatment Market Dynamics – Trends |
| 15. Middle East and Africa Lung Cancer Treatment Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn) |
| 15.1. Surgery Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.1.1. Lobectomy |
| 15.1.2. A wedge resection |
| 15.1.3. Segmentectomy |
| 15.1.4. Pneumonectomy |
| 15.2. Chemotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.2.1. Carboplatin or cisplatin |
| 15.2.2. Docetaxel (Taxotere) |
| 15.2.3. Gemcitabine (Gemzar) |
| 15.2.4. Nab-paclitaxel (Abraxane) |
| 15.2.5. Paclitaxel (Taxol) |
| 15.2.6. Pemetrexed (Alimta) |
| 15.2.7. Vinorelbine (Navelbine) |
| 15.3. Radiotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 15.3.1. External Beam |
| 15.3.2. Internal Beam |
| 15.4. Targeted therapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.4.1. Epidermal growth factor receptor (EGFR) inhibitors |
| 15.4.2. Anaplastic lymphoma kinase (ALK) inhibitors |
| 15.4.3. Drugs targeting ROS1 genetic changes |
| 15.4.4. Drugs targeting RET fusion |
| 15.4.5. Anti-angiogenesis therapy |
| 15.5. Immunotherapy Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 15.5.1. Atezolizumab (Tecentriq) |
| 15.5.2. Cemiplimab (Libtayo) |
| 15.5.3. Durvalumab (Imfinzi) |
| 15.5.4. Nivolumab (Opdivo) |
| 15.5.5. Pembrolizumab (Keytruda) |
| 15.6. Country Analysis 2017-2021 and Forecast 2022-2028 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 15.6.1. Gulf Cooperation Council (GCC) Countries |
| 15.6.2. South Africa |
| 15.6.3. Rest of MEA |
| 15.7. MEA Lung Cancer Treatment Market - Opportunity Analysis Index, By Surgery, Chemotherapy, Radiotherapy, Targeted therapy, Immunotherapy and Country, 2022-2028 |
| 15.8. MEA Lung Cancer Treatment Market Dynamics – Trends |
| 16. Competition Landscape |
| 16.1. Strategic Dashboard of Top Market Players |
| 16.2. Company Profiles (Introduction, Financial Analysis, Key Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 16.2.1. Boehringer Ingelhein GmbH |
| 16.2.2. Hoffman La- Roche |
| 16.2.3. Pfizar Inc. |
| 16.2.4. Astrazeneca Plc. |
| 16.2.5. GlaxoSmithKline |
| 16.2.6. Eli Lilly and Company |
| 16.2.7. Agennix AG |
| 16.2.8. Sanofi-Aventi |
| 17. Research Methodology |
| 18. Key Assumptions and Acronyms |
hghLatin America Got Significant Share
Lung Cancer Treatment Market
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share and forecast from 2021-2027
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- Boehringer Ingelhein GmbH
- Hoffman La- Roche
- Pfizar Inc.
- Astrazeneca Plc.
- GlaxoSmithKline
- Eli Lilly and Company
- Agennix AG
- Sanofi-Aventi